Flexion Therapeutics Inc Form 3 February 11, 2014

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL

OMB Number:

3235-0104 January 31,

0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Expires: 2005
Estimated average

burden hours per response...

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting 2. Date of Event Requiring 3. Issuer Name and Ticker or Trading Symbol Person * Statement Flexion Therapeutics Inc [FLXN] Novo A/S (Month/Day/Year) 02/11/2014 (Last) (First) (Middle) 4. Relationship of Reporting 5. If Amendment, Date Original Person(s) to Issuer Filed(Month/Day/Year) **TUBORG HAVNEVEJ 19** (Check all applicable) (Street) 6. Individual or Joint/Group Filing(Check Applicable Line) Director _X__ 10% Owner _X_ Form filed by One Reporting Officer __X__ Other Person HELLERUP, G7Â 2900 (give title below) (specify below) Form filed by More than One SEE REMARKS Reporting Person (City) (State) (Zip) Table I - Non-Derivative Securities Beneficially Owned 4. Nature of Indirect Beneficial 1. Title of Security 2. Amount of Securities Beneficially Owned Ownership (Instr. 4) Ownership (Instr. 4) Form: (Instr. 5) Direct (D) or Indirect (I) (Instr. 5) Reminder: Report on a separate line for each class of securities beneficially SEC 1473 (7-02) owned directly or indirectly. Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a

currently valid OMB control number.

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security		4. Conversion or Exercise	5. Ownership Form of	
	Date Exercisable	Expiration Date	(Instr. 4) Title	Amount or Number of Shares	Price of Derivative Derivative Security: Security Direct (D) or Indirect (I) (Instr. 5)	(Instr. 5)	

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

Edgar Filing: Flexion Therapeutics Inc - Form 3

(1)

SERIES B PREFERRED **STOCK**

(1)

 $\hat{\mathbf{A}}$ $\underline{^{(1)}}$

COMMON STOCK

1.090,823 \$0 D Â

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Novo A/S

TUBORG HAVNEVEJ 19 HELLERUP, Â G7Â 2900

Â ÂX Â

SEE REMARKS

Signatures

/s/ Thorkil Kastberg Christensen, Chief Financial Officer of Novo A/S

02/11/2014

**Signature of Reporting Person

Date

Explanation of Responses:

- If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Represents 8,868,393 shares of Series B Preferred Stock (the "Preferred Stock"), which has no expiration date and is convertible at any time, at the holder's election. Upon the closing of the Issuer's initial public offering, the Preferred Stock will automatically convert into

shares of the Issuer's Common Stock based on the then-applicable Conversion Price (as defined in the Issuer's Amended and Restated **(1)** Certificate of Incorporation), which currently provides for conversion on a 1-for-8.13 basis after automatically adjusting to reflect the 1-for-8.13 reverse stock split of the Issuer's common stock that occurred on January 27, 2014.

Â

Remarks:

Novo A/S is a Danish limited liability company. Â The board of directors of Novo A/S (the "Nov

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

Reporting Owners 2